vimarsana.com

Latest Breaking News On - Hr positive breast cancer - Page 1 : vimarsana.com

The Role of Elacestrant in Breast Cancer

Erica L. Mayer, MD, MPH, discusses the role of elacestrant in the breast cancer treatment landscape and provides clinical insights on its safety profile.

Erical-mayer
Breast-cancer
Hr-breast-cancer
Hr-positive-breast-cancer
Breast-cancer-treatment
Esr1
Esr1-mutations
Elacestrant
Endocrine-therapies
Emerald-study
Emerald-trial

SERENA-2: Camizestrant vs Fulvestrant in Advanced ER+/HER2- Breast Cancer

Medical oncologists discuss oral SERDs, with a focus on the SERENA-2 trial looking at camizestrant in patients with advanced ER+/HER2- breast cancer.

Breast-cancer
Hr-breast-cancer
Hr-positive-breast-cancer
Breast-cancer-treatment
Esr1
Esr1-mutations
Oral-serds
Serds
Serena-2
Adverse-effects
Camizestrant

PADA-1 Trial: ctDNA Monitoring for Acquired ESR1 Mutations in Advanced Breast Cancer

Drs Mayer and Kalinsky provide insights and offer their impressions of the PADA-1 trial, focusing on ESR1 mutation monitoring with circulating tumor DNA (ctDNA).

Breast-cancer
Advanced-breast
Hr-breast-cancer
Hr-positive-breast-cancer
Breast-cancer-treatment
Esr1
Esr1-mutations
Biomarker-testing
Esr1-testing
Pada-1
Ctdna

EMERALD: Elacestrant in ER+/HER2- Advanced Breast Cancer

Kevin Kalinsky, MD, MS, gives an overview of recent data from the EMERALD trial investigating elacestrant in patients with ER+/HER2- advanced breast cancer.

Kevin-kalinsky
Breast-cancer
Hr-breast-cancer
Hr-positive-breast-cancer
Breast-cancer-treatment
Esr1
Esr1-mutations
Emerald-study
Emerald-trial
Elacestrant

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.